Edwards Lifesciences (EW)
NYSEHealth CareMedical DevicesSnapshot 2026-07-07
$94.82-0.38%
Close 2026-07-07 · 1-day change
Reading EW? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EW free→NYSEHealth CareMedical DevicesSnapshot 2026-07-07
Reading EW? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EW free→Edwards Lifesciences grows sales about 10% a year. Profit rises with EPS near $3.00 in 2026. TAVR sales expand steadily, reaching $1.2 billion in Q1 2026. The company benefits from a rival's setback, strengthening its market position.
Growth could slow if TAVR sales falter or competition intensifies. EPS might miss guidance if costs rise. Regulatory or leadership changes could disrupt execution.
The price is about 18% above our fair value near $80. Analysts expect 11.5% revenue growth, which aligns with company guidance. Our fair value is below the Street median, reflecting a cautious view on margin and growth sustainability.
Breaks if: EPS falls below $2.95 in FY 2026
Edwards Lifesciences is raising the midpoint of its full-year adjusted EPS guidance.
Stated in 2 of last 2 quarters. EPS increased from $0.61 in 2025-Q1 to $0.66 in 2026-Q1. The company raised its FY 2026 adjusted EPS guidance midpoint to $2.95 to $3.05, showing progress in this area.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Raising FY 2026 adjusted EPS guidance midpoint; new range of $2.95 to $3.05 from $2.90 to $3.05.”
“Increased confidence in FY 2026 adjusted EPS $2.90 – $3.05.”
Breaks if: Revenue falls below $6.5 billion in FY 2026
Edwards Lifesciences aims to increase its sales growth guidance for 2026.
Stated in 2 of last 2 quarters. Revenue grew from $1.41 billion in 2025-Q1 to $1.65 billion in 2026-Q1, reflecting a 16.7% increase. The company has raised its FY 2026 sales growth guidance to 9% to 11%, indicating delivering on this priority.
“Raising FY 2026 constant currency sales growth guidance to 9% to 11% from 8% to 10%.”
“Increased confidence in FY 2026 constant currency sales growth of 8 – 10%.”
Breaks if: TAVR sales growth falls below 7% in FY 2026
Edwards Lifesciences is expanding its TAVR sales growth guidance for 2026.
Stated in 2 of last 2 quarters. TAVR sales grew 14.4% to $1.20 billion in 2026-Q1. The company raised its full-year 2026 TAVR sales growth guidance to 7% to 9%, indicating positive momentum in this segment.
“Raising full-year 2026 TAVR sales growth guidance to 7% to 9% from 6% to 8%.”
“FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million.”